Jetzt anmelden und diskutieren
Registrieren
Login
Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA
NEW YORK, April 22, 2026 /PRNewswire/ -- IMPORTANT DATE: May 5, 2026. Investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025 and wish to seek appointment as lead plaintiff must file a motion by this date. Start your claim now before the deadline. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
NKTR shares fell $4.14 per share, or 7.77%, on December 16, 2025, after the Company disclosed that four ineligible patients had been included in its pivotal REZOLVE-AA Phase 2b trial, causing the primary endpoint to miss statistical significance.
What is a Lead Plaintiff?
Under the Private Securities Litigation Reform Act of 1995 ("PSLRA"), the lead plaintiff is the investor or group of investors appointed by the Court to represent the class. In the Nektar action, pending in the U.S. District Court for the Northern District of California, the lead plaintiff will direct litigation strategy on behalf of all purchasers during the Class Period. Any class member may move for appointment; the Court generally selects the applicant with the largest financial interest in the relief sought.
Lead Plaintiff Facts
Absent Class Member Rights
Shareholders who do not seek lead plaintiff status remain members of the class. If a recovery is achieved, absent class members will receive notice and an opportunity to submit a claim. No action is required to preserve your right to participate in any future recovery.
"The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests in the outcome. In the Nektar matter, where trial enrollment violations allegedly caused NKTR shares to lose $4.14 per share, lead plaintiff appointment carries meaningful responsibility." -- Joseph E. Levi, Esq.
Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
View original content to download multimedia:https://www.prnewswire.com/news-releases/nktr-investor-alert-nektar-therapeutics-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-allegedly-concealing-enrollment-violations-levi--korsinsky-302749902.html
SOURCE Levi & Korsinsky, LLP
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
